New hope for breast cancer brain metastases: drug combo plus radiation shows promise

NCT ID NCT07396454

Recruiting now Disease control Sponsor: The First Affiliated Hospital with Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether adding two drugs (anlotinib and a tubulin inhibitor) to standard radiation therapy can help control HER2-negative breast cancer that has spread to the brain. About 39 women aged 18-70 will receive radiation followed by the drug combination. The main goal is to see how long the cancer in the brain stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Anlotinib (a drug that blocks blood vessel growth) plus a tubulin inhibitor (a chemotherapy drug)
What this could lead to: If successful, this combination could offer a new treatment option to control brain metastases in HER2-negative breast cancer patients.
What could go wrong: This is a small, early-phase trial with only 39 participants, so results may not apply to everyone. The combination may cause side effects and might not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Her2-receptor negative breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-NEGATIVE BREAST CANCER

Contacts and locations

Locations

The First Affiliated Hospital of Nanjing Medical University
RECRUITING

Nanjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.